IHE
iShares U.S. Pharmaceuticals ETF
Set alert
107.61 USD +1.00 +0.94%
107.29 Day range 109.43
75.26 52-week range 108.16
- YTD
- +26.85%
- 1 year
- +42.98%
- Open
- 108.43
- Prev close
- 106.61
- Mkt cap
- 1.21B
- Vol
- 395.46K
- Avg vol
- 225.76K
- EPS
- 3.82
- P/E
- 28.18
- Div yield
- 0.00%
More statistics
- Low
- 107.29
- High
- 109.43
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 102.38
- 200-d avg
- 94.66
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 28.17
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 102.38
- 200-day average
- 94.66
About iShares U.S. Pharmaceuticals ETF
The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The fund is non-diversified.
News
- Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today
- Capital Investment Advisors LLC Makes New $630,000 Investment in iShares U.S. Pharmaceuticals ETF $IHE
- Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?
- From Laggard to Leader: The Surprising Comeback of Healthcare
- Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?
- Better Pharma ETF: iShares IHE vs. State Street XPH
- Execution of Pharma Tariffs Brings These ETFs Into Focus
- Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
- IHE: Innovation Supports The Outlook, Valuation Limits Conviction
- IHE: Large-Cap Pharma Cools After A Hot Summer
Your note
Sign in to keep a note on IHE — it syncs with the Stock Master app.